{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-120687","form_type":"8-K","ticker":"ACHV","cik":"0000949858","company_name":"ACHIEVE LIFE SCIENCES, INC.","filed_at":"2026-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.099260+00:00","generated_at":"2026-05-15T09:18:55.117421+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Achieve Life Sciences reports Q4/FY2025 net loss $54.7M; cytisinicline NDA PDUFA June 20, 2026","bullets":["Cash $36.4M at Dec 31, 2025; net loss $14.7M Q4 and $54.7M FY2025.","FDA accepted cytisinicline NDA for smoking cessation; PDUFA action date June 20, 2026.","Partnered with Adare Pharma Solutions for US-based manufacturing; tech transfer begun.","Anticipates US commercial launch in first half 2027.","Completed ORCA-OL one-year safety study with 334 participants."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-120687","json":"https://secwatch.observer/filing/0001193125-26-120687.json","markdown":"https://secwatch.observer/filing/0001193125-26-120687.md","text":"https://secwatch.observer/filing/0001193125-26-120687.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/949858/000119312526120687/0001193125-26-120687-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/949858/000119312526120687/achv-20260324.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:18:55.117421+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"83db457c3bb39e412a59784b08230d8b5d79e930","claim":"ACHIEVE LIFE SCIENCES, INC. reported the fourth quarter and full year ended December 31, 2025 results: net income Total net loss for the three and twelve months ended December 31, 2025, was $14.7 million and $54.7 million, respectivel.","evidence_excerpt":"On March 24, 2026, Achieve Life Sciences, Inc. issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/949858/000119312526120687/0001193125-26-120687-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2025"},{"label":"Net income","value":"Total net loss for the three and twelve months ended December 31, 2025, was $14.7 million and $54.7 million, respectivel"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}